Angiolymphoid hyperplasia with eosinophilia: Difference between revisions

Jump to navigation Jump to search
Line 31: Line 31:
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Angiolymphoid hyperplasia with eosinophilia is more commonly observed among young patients.
*[Disease name] is more commonly observed among patients aged [age range] years old.
*[Disease name] is more commonly observed among [elderly patients/young patients/children].
===Gender===
===Gender===
*Females are more commonly affected with angiolymphoid hyperplasia with eosinophilia than males.
*Females are more commonly affected with angiolymphoid hyperplasia with eosinophilia than males.
===Race===
===Race===
*Angiolymphoid hyperplasia with eosinophilia usually affects predominently individuals of the Asian race.
*Angiolymphoid hyperplasia with eosinophilia usually affects predominently individuals of the Asian race.

Revision as of 19:30, 9 May 2016

WikiDoc Resources for Angiolymphoid hyperplasia with eosinophilia

Articles

Most recent articles on Angiolymphoid hyperplasia with eosinophilia

Most cited articles on Angiolymphoid hyperplasia with eosinophilia

Review articles on Angiolymphoid hyperplasia with eosinophilia

Articles on Angiolymphoid hyperplasia with eosinophilia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Angiolymphoid hyperplasia with eosinophilia

Images of Angiolymphoid hyperplasia with eosinophilia

Photos of Angiolymphoid hyperplasia with eosinophilia

Podcasts & MP3s on Angiolymphoid hyperplasia with eosinophilia

Videos on Angiolymphoid hyperplasia with eosinophilia

Evidence Based Medicine

Cochrane Collaboration on Angiolymphoid hyperplasia with eosinophilia

Bandolier on Angiolymphoid hyperplasia with eosinophilia

TRIP on Angiolymphoid hyperplasia with eosinophilia

Clinical Trials

Ongoing Trials on Angiolymphoid hyperplasia with eosinophilia at Clinical Trials.gov

Trial results on Angiolymphoid hyperplasia with eosinophilia

Clinical Trials on Angiolymphoid hyperplasia with eosinophilia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Angiolymphoid hyperplasia with eosinophilia

NICE Guidance on Angiolymphoid hyperplasia with eosinophilia

NHS PRODIGY Guidance

FDA on Angiolymphoid hyperplasia with eosinophilia

CDC on Angiolymphoid hyperplasia with eosinophilia

Books

Books on Angiolymphoid hyperplasia with eosinophilia

News

Angiolymphoid hyperplasia with eosinophilia in the news

Be alerted to news on Angiolymphoid hyperplasia with eosinophilia

News trends on Angiolymphoid hyperplasia with eosinophilia

Commentary

Blogs on Angiolymphoid hyperplasia with eosinophilia

Definitions

Definitions of Angiolymphoid hyperplasia with eosinophilia

Patient Resources / Community

Patient resources on Angiolymphoid hyperplasia with eosinophilia

Discussion groups on Angiolymphoid hyperplasia with eosinophilia

Patient Handouts on Angiolymphoid hyperplasia with eosinophilia

Directions to Hospitals Treating Angiolymphoid hyperplasia with eosinophilia

Risk calculators and risk factors for Angiolymphoid hyperplasia with eosinophilia

Healthcare Provider Resources

Symptoms of Angiolymphoid hyperplasia with eosinophilia

Causes & Risk Factors for Angiolymphoid hyperplasia with eosinophilia

Diagnostic studies for Angiolymphoid hyperplasia with eosinophilia

Treatment of Angiolymphoid hyperplasia with eosinophilia

Continuing Medical Education (CME)

CME Programs on Angiolymphoid hyperplasia with eosinophilia

International

Angiolymphoid hyperplasia with eosinophilia en Espanol

Angiolymphoid hyperplasia with eosinophilia en Francais

Business

Angiolymphoid hyperplasia with eosinophilia in the Marketplace

Patents on Angiolymphoid hyperplasia with eosinophilia

Experimental / Informatics

List of terms related to Angiolymphoid hyperplasia with eosinophilia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2] Ammu Susheela, M.D. [3]

Synonyms and Keywords: Epithelioid hemangioma; Histiocytoid hemangioma; Inflammatory angiomatous nodule; Intravenous atypical vascular proliferation; Papular angioplasia; Inflammatory arteriovenous hemangioma; Pseudopyogenic granuloma; ALHE

Overview

Angiolymphoid hyperplasia with eosinophilia [1] is defined as red-brown, dome-shaped, dermal papule or nodule, present in the head or neck, specifically around the ears and on the scalp.[2]

Historical Perspective

  • Angiolymphoid hyperplasia with eosinophilia was first discovered by G. C. WELLS andI. W. WHIMSTER, two british physicians , in 1969.[3]

Pathophysiology

  • The pathogenesis of angiolymphoid hyperplasia with eosinophilia is characterized by red to brown papules or nodules dislocated in the dermis or subcutaneous tissue.
  • Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare and idiopathic vascular disorder.
  • Angiolymphoid hyperplasia with eosinophilia (ALHE) is an uncommon benign lesion, primarily occurring in the head and neck.
  • On gross pathology, smooth-surface red to brown papules or nodules on the head, neck, trunk, extremities, genitalia, lips and oral mucosa; extracutaneous involvement are characteristic findings of angiolymphoid hyperplasia with eosinophilia.
  • On microscopic histopathological analysis, florid vascular proliferation with atypical endothelial cells surrounded by a lymphocytic and eosinophilic infiltrate are characteristic findings of angiolymphoid hyperplasia with eosinophilia.

Causes

  • Angiolymphoid hyperplasia with eosinophilia may be caused by either allergic reactions, traumas, or autoimmune disorders.

Differentiating Angiolymphoid hyperplasia with eosinophilia from other Diseases

  • Angiolymphoid hyperplasia with eosinophilia must be differentiated from other diseases that cause swelling of face and neck, such as:
  • Kimura’s disease
  • Acial granuloma
  • Insect bite reaction
  • Cutaneous lymphoma
  • Sarcoidosis

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Angiolymphoid hyperplasia with eosinophilia is more commonly observed among young patients.

Gender

  • Females are more commonly affected with angiolymphoid hyperplasia with eosinophilia than males.

Race

  • Angiolymphoid hyperplasia with eosinophilia usually affects predominently individuals of the Asian race.

Risk Factors

  • Common risk factors in the development of angiolymphoid hyperplasia with eosinophilia are allergic reactions, traumas or autoimmune disorders.

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for

[duration/years].

  • Early clinical features include [manifestation 1], [manifestation 2],

and [manifestation 3].

  • If left untreated, [#%] of patients with [disease name] may progress

to develop [manifestation 1], [manifestation 2], and [manifestation 3].

  • Common complications of [disease name] include [complication 1],

[complication 2], and [complication 3].

  • Prognosis is generally [excellent/good/poor], and the [1/5/10year

mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the

following [number] diagnostic criteria are met:

  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease

name].

  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of

[serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].

  • Other laboratory findings consistent with the diagnosis of [disease

name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease

name].

  • On [imaging study 1], [disease name] is characterized by [finding 1],

[finding 2], and [finding 3].

  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and

[finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2],

and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is

supportive care.

  • The mainstay of therapy for [disease name] is [medical therapy 1] and

[medical therapy 2].

  • [Medical therapy 1] acts by [mechanism of action1].
  • Response to [medical therapy 1] can be monitored with [test/physical

finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for angiolymphoid hyperplasia with eosinophilia.
  • Mohs micrographic surgery with complete margin examination is performed.
  • Other treatment options include radiotherapy, curettage, shave excision with electrodessication, cryotherapy, corticosteroids (topical, systemic or intralesional preparation), and laser therapy using Continuous wave carbon dioxide and argon lasers.[4]

Prevention

  • There are no primary preventive measures available for [disease

name].

  • Effective measures for the primary prevention of [disease name]

include [measure1], [measure2], and [measure3].

  • Once diagnosed and successfully treated, patients with [disease name]

are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].

Diagnosis

Ear

References

  1. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
  2. James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
  3. Wells GC, Whimster IW (1969). "Subcutaneous angiolymphoid hyperplasia with eosinophilia". Br J Dermatol. 81 (1): 1–14. PMID 5763634.
  4. Lembo S, Balato A, Cirillo T, Balato N (2011). "A Long-Term Follow-Up of Angiolymphoid Hyperplasia with Eosinophilia Treated by Corticosteroids: When a Traditional Therapy is Still Up-to-Date". Case Rep Dermatol. 3 (1): 64–7. doi:10.1159/000323182. PMC 3073756. PMID 21487464.